Want to Calculate Fair Value?
Enter Stock | Calculate Fair Value
Stock: NBIX
Book Value Per Share: $25.61
EPS: $4.19
Diluted EPS TTM: $2.95
Dividend Per Share: None
Dividend Yield: 0.00 %
Dividend Payout Ratio: 0%
Price To Sales Ratio TTM: 5.19
Price To Book Ratio: 4.939
PEG Ratio: 0.273
EV To EBITDA: 21.5
P/E Ratio: 42.9
Forward P/E Ratio: 24.57
Ex Dividend Date: 1995-12-29
Dividend Date: None
Current Price: $131.24
Previous Close: $135.13
52 Week Low: $84.23
52 Week High: $157.98
Earning Date (within 30 days): 2025-07-30
50 Day MA: $115.12
200 Day MA: $121.3
Link to Yahoo (Financial): NBIX

Advertisement
 
* Note: Prices are in Million (M) USD.
Description:
Neurocrine Biosciences Inc (NBIX) ↓
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $233 M
Debt : $0 M
EBITDA : $530 M

Since Cash is greater than Total Debt, 5 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology

Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 31.32

Since Forward PE Ratio is between 25 - 35, 1 point assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $305 M
Average Revenue: $484 M
Revenue Converted To Free Cash FLow(%): 63%
Avg Free Cash Flow Growth Per Year (Last 5 Years): 34.04%

Since Free Cash Flow (FCF) to Revenue percentage is greater than 25, 5 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $2,355 M
Revenue 4 Years Ago (2020-12-31): $1,046 M
Last 5 Years Average Revenue Growth: 25%

Since Revenue Growth is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $104 M
Share Count 5 Years Ago (2020-12-31): $98 M

Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $5.28
Trailing 12-Month Earnings Per Share (EPS): $3.10
Average Earnings Per Share (EPS): $4.19
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%

Since Dividend Per Share is less than or equal to 0, 0 point assigned.

Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -90%

Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $131
52-Week Low: $84
Threshold Price (15% Above 52-Week Low): $97

Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $12,524 M

Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the calculated score, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 23 points to above Neurocrine Biosciences Inc (NBIX) stock.
Last 10 Years Avg PE (Limited to last 10 years of EPS data) 40, Fair Value PE 25, Industry Based PE is 20 and Growth based PE is 15. Based on these all values average assigned is 25.00.
Value-Trades has assined P/E value 25.00. Since an average (Current Year EPS + Next Year EPS) earning per share is $4.19.
The fair value of Neurocrine Biosciences Inc (NBIX) stock should be (25.00 x $4.19) = $104.75

Share this valuation:



Advertisement

Advertisement